Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for chemotherapy-induced thrombocytopenia in solid tumors
NCT03976882Phase 3Completed
- Sponsor
- Hengrui
- Start
- Nov 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Hengrui. Started Nov 2019; status: completed.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT03976882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976882.